Unicycive Therapeutics Inc
UNCY4.204USD
+0.114+2.78%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
59.32MCap. mercado
PérdidaP/E TTM
Más Datos de Unicycive Therapeutics Inc Compañía
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Información de la empresa
Símbolo de cotizaciónUNCY
Nombre de la empresaUnicycive Therapeutics Inc
Fecha de salida a bolsaJun 17, 2021
Director ejecutivoDr. Shalabh Gupta, M.D.
Número de empleados22
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 17
Dirección4300 El Camino Real, Suite 210
CiudadLOS ALTOS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94022
Teléfono16503840642
Sitio Webhttps://unicycive.com/
Símbolo de cotizaciónUNCY
Fecha de salida a bolsaJun 17, 2021
Director ejecutivoDr. Shalabh Gupta, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
Otro
74.64%
Accionistas
Accionistas
Proporción
Vivo Capital, LLC
6.44%
Octagon Capital Advisors LP
5.66%
Nantahala Capital Management, LLC
5.32%
Great Point Partners, LLC
4.51%
The Vanguard Group, Inc.
3.43%
Otro
74.64%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
24.67%
Venture Capital
12.61%
Individual Investor
4.93%
Investment Advisor
4.75%
Investment Advisor/Hedge Fund
0.73%
Research Firm
0.19%
Otro
52.11%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
2023Q1
38
9.94M
65.95%
+1.31M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Vivo Capital, LLC
1.14M
8.9%
+140.00K
+14.04%
Mar 31, 2025
Octagon Capital Advisors LP
1.00M
7.83%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
939.20K
7.36%
-100.00K
-9.62%
Mar 31, 2025
Great Point Partners, LLC
1.10M
8.6%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
121.24K
0.95%
+7.42K
+6.52%
Mar 31, 2025
Gupta (Shalabh K)
597.25K
4.68%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
507.89K
3.98%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
242.49K
1.9%
+242.49K
--
Apr 30, 2025
Armistice Capital LLC
97.60K
0.76%
--
--
Dec 31, 2023
Acuta Capital Partners, LLC
235.29K
1.84%
+4.99K
+2.17%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
